Actions
Pages
Subscribe for newsletter
Stories
IO Research's decentralized physical infrastructure network (DePIN), io.net, built on Solana, has reached a $1 billion fully diluted token valuation following its latest Series A funding round.
The rapid ascent of io.net's valuation marks an important moment in the democratization of computing resources, heralding a new era where AI and machine learning (ML) development are bound by fewer constraints.
This milestone arrives at a time when the demand for GPU computing power is skyrocketing. By leveraging decentralized networks like io.net, the industry can access a much-needed solution to the global GPU scarcity, ensuring the continued advancement of AI technologies without the hefty price tag.
io.net leverages the Solana blockchain for transparent proof-of-compute, enhancing transaction visibility between suppliers and consumers. The IO token facilitates a unified transaction experience and incentivizes network participation and growth, claiming to reduce cloud AI costs by up to 90% for customers in the face of a global GPU shortage.
"Io.net saves customers up to 90% on their cloud AI costs. In an age where GPU chips are in high demand with global shortages, that is simply an incredible accomplishment," stated Ed Roman, managing partner at Hack VC.
With the native IO token set to launch on April 28, the future looks bright for io.net. The platform is poised for significant growth, aiming to double its workforce by year-end to accelerate development and meet escalating demand. This expansion is a testament to io.net's potential to revolutionize how we approach GPU computing for AI and ML.
The innovative use of blockchain for proof-of-compute ensures transparency and efficiency, exemplifying how decentralized solutions can overcome traditional barriers in technology sectors. io.net's model could serve as a blueprint for future endeavors aiming to tackle similar challenges across various industries.
io.net exemplifies the transformative power of decentralization in technology, achieving a $1 billion token valuation that not only signifies financial success but also highlights a significant shift towards more accessible and affordable computing resources. Platforms like io.net are essential in ensuring these technologies can grow unencumbered by current limitations.
Story
AWS has acquired Talen Energy's Cumulus Data data center campus in Pennsylvania for $650 million, which is located at a nuclear power station and includes all the land, power infrastructure, and intangibles.
AWS plans to develop up to a 960MW data center campus in northeast Pennsylvania, with two 10-year extension options tied to nuclear license renewals and minimum contractual power commitments that ramp up in 120 MW increments.
Talen Energy will supply AWS with direct-connect, carbon-free power for the data center campus, and under a separate agreement, Talen will also receive additional revenue from AWS related to sales of carbon-free energy to the grid.
Talen Energy, founded in 2015, established Cumulus Growth in 2020, comprising Cumulus Data for hyperscale data centers and Cumulus Coin for digital currency mining.
There are numerous synergies between datacenter infrastructure and cryptocurrency mining sites, so similar acquisitions are likely to occur in the future.
AWS's acquisition of a nuclear-powered data center campus underscores the tech industry's shift towards sustainable energy solutions, with significant implications for the future of data center operations and green energy adoption.
While nuclear power offers a carbon-free energy source, concerns about nuclear waste and safety remain, highlighting the need for continued innovation in sustainable energy technologies.
Story
The biotech industry is witnessing a revival in the early months of 2024 with a series of IPOs worth around $100 million or more and startup financings. This uptick, along with the recovery of biotech’s flagship stock funds and a surge in dealmaking, has sparked optimism about the industry's health.
The recent success stories include companies like CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma, which not only raised more funds than anticipated but also saw their stock prices increase post-IPO. Biotech venture capital has pulled in approximately $15 billion annually in the last two years.
Invivo Partners, a Barcelona-based venture capital firm, is close to securing a new fund of €100 million ($109 million), with a potential to extend up to €120 million, marking its third fund since inception. The firm has conducted notable acquisitions like Sanifit Therapeutics by Vifor Pharma for €205 million and Versantis by Genfit for about €43 million.
However, the sustainability of this IPO resurgence remains uncertain. Following a brisk period of activity in late January and early February, no new IPO plans have been announced.
Observers are cautiously watching whether this initial burst will translate into sustained growth for the sector or if it represents a temporary spike in a typically volatile market landscape.
The IPO slowdown since late 2021 has had a cascading effect on venture funding for biotech startups, making it more challenging to raise funds at desirable valuations.
The focus on late-stage, de-risked investments raises questions about the financing landscape for early-stage biotech innovators and whether a shift in investor sentiment could broaden the pool of IPO candidates.
This current wave of investment aligns with a broader investor thesis that views biotech as a ripe area for growth, driven by technological advancements and an increasing demand for healthcare innovation.
Story
Innovators
Scroll
Open
Close